Cellebrite DI (CLBT) EBITDA (2020 - 2025)

Cellebrite DI (CLBT) has reported EBITDA for 6 consecutive years, with $21.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, EBITDA changed 0.4% year-over-year to $21.0 million; the TTM figure through Dec 2025 stood at $78.5 million (down 75.77% YoY), while the FY2025 annual figure was $78.5 million, down 72.17% from the prior year.
• EBITDA came in at $21.0 million for Q4 2025 at Cellebrite DI, up from $20.0 million in the prior quarter.
• The five-year high for EBITDA was $207.9 million in Q3 2024, with the low at -$41.1 million in Q1 2023.
• Average EBITDA over 5 years is $26.3 million, with a median of $20.5 million recorded in 2024.
• Across the five-year window, EBITDA slumped 270.95% in 2023 and jumped 2719.35% in 2024, its largest moves.
• Year by year, EBITDA stood at $1.4 million in 2021, then soared by 464.34% to $8.2 million in 2022, then plunged by 270.95% to -$14.0 million in 2023, then soared by 249.68% to $20.9 million in 2024, then increased by 0.4% to $21.0 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered $21.0 million, $20.0 million, and $21.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.